Nature· Amanda Heidt·· 16 hours agoPickScore79
Will this sleep-disorder drug be the next big blockbuster?
In brief
Takeda's Orzeyful (oveporexton) became the first orexin receptor agonist approved by the FDA for narcolepsy, and multiple researchers think the class could expand beyond sleep disorders much as GLP-1 drugs did. The article traces orexin's independent discovery in the 1990s by teams at Scripps and UT Southwestern, and cites analysts projecting the global narcolepsy drug market to exceed $6.4 billion by 2031.
Why it matters
The article links orexin's 1990s basic discovery to the first approved drug and uses the GLP-1 analogy to explain expectations for expanding indications.
Source: Nature